MDxHealth (R): Multi-center Study Validates SelectMDx's High Negative Predictive Value and Sensitivity
10 Juin 2019 - 7:00AM
Multi-center 1,955 patient study published in the Journal
of Urology
IRVINE, CA, and HERSTAL, BELGIUM - Jun 10, 2019 - MDxHealth SA
(Euronext: MDXH.BR), a commercial-stage innovative molecular
diagnostics company, today announced that a second clinical
validation study demonstrating the performance of its liquid biopsy
test SelectMDx for Prostate Cancer has been published in the
The Journal of Urology.
In a clinical study of 1,955 men
undergoing initial prostate biopsy, SelectMDx yielded a 95%
negative predictive value and 93% sensitivity for the detection of
clinically significant prostate cancer. These data support the use
of SelectMDx to help physicians determine which patients are at
risk of aggressive prostate cancer and help guide initial prostate
biopsy decisions.
"The publication of these
compelling data clearly demonstrate the clinical validity and value
proposition of our SelectMDx test. We look forward to continued
progress on the adoption and coverage of our SelectMDx test in both
the U.S. and Europe," stated Michael McGarrity, CEO of
MDxHealth.
The full paper is accessible via
The Journal of Urology
Haese A. et al.; Multicenter
Optimization and Validation of a 2-Gene mRNA Urine Test for
Detection of Clinically Significant Prostate Cancer Prior to
Initial Prostate Biopsy. Journal of Urology 2019
For more
information:
Consilium Strategic Communications
Amber Fennell, Chris Welsh, David Daley
UK: +44 20 3709 5701
mdxhealth@consilium-comms.com |
About MDxHealth
MDxHealth is a multinational
healthcare company that provides actionable molecular diagnostic
information to personalize the diagnosis and treatment of cancer.
The company's tests are based on proprietary genetic, epigenetic
(methylation) and other molecular technologies and assist
physicians with the diagnosis of urologic cancers, prognosis of
recurrence risk, and prediction of therapeutic response. The
Company's European headquarters are in Herstal, Belgium, with
laboratory operations in Nijmegen, The Netherlands, and US
headquarters and laboratory operations based in Irvine, California.
For more information, visit mdxhealth.com.
Disclaimer
This press release contains forward-looking statements and
estimates with respect to the anticipated future performance of
MDxHealth and the market in which it operates. Such statements and
estimates are based on assumptions and assessments of known and
unknown risks, uncertainties and other factors, which were deemed
reasonable but may not prove to be correct. Actual events are
difficult to predict, may depend upon factors that are beyond the
company's control, and may turn out to be materially different.
MDxHealth expressly disclaims any obligation to update any such
forward-looking statements in this release to reflect any change in
its expectations with regard thereto or any change in events,
conditions or circumstances on which any such statement is based
unless required by law or regulation. This press release does
not constitute an offer or invitation for the sale or purchase of
securities or assets of MDxHealth in any jurisdiction. No
securities of MDxHealth may be offered or sold within the United
States without registration under the U.S. Securities Act of 1933,
as amended, or in compliance with an exemption therefrom, and in
accordance with any applicable U.S. securities laws.
NOTE: The MDxHealth logo, MDxHealth, ConfirmMDx,
SelectMDx, AssureMDx, PredictMDx and UrNCollect are trademarks or
registered trademarks of MDxHealth SA. All other trademarks and
service marks are the property of their respective owners.
200519 SelectMDx
JOU_JG[2][1]
This
announcement is distributed by West Corporation on behalf of West
Corporation clients.
The issuer of this announcement warrants that they are solely
responsible for the content, accuracy and originality of the
information contained therein.
Source: MDxHealth (R) via Globenewswire
MDxHealth (EU:MDXH)
Graphique Historique de l'Action
De Avr 2024 à Mai 2024
MDxHealth (EU:MDXH)
Graphique Historique de l'Action
De Mai 2023 à Mai 2024